Effect of nateglinide on the incidence of diabetes and cardiovascular events

R Holman; Steven Haffner; John McMurray; M Bethel; Bjoern Holzhauer; Tsushung Hua; Yuri Belenkov; Mitradev Boolell; John Buse; Brendan Buckley; Antonio Chacra; Fu-Tien Chiang; Bernard Charbonnel; Chun-Chung Chow; Melanie Davies; Prakash Deedwania; Peter Diem; Daniel Einhorn; Vivian Fonseca; Gregory Fulcher; Zbigniew Gaciong; Sonia Gaztambide; Thomas Giles; Edward Horton; Hasan Ilkova; Trond Jenssen; Steven Kahn; Henry Krum; Markku Laakso; Lawrence Leiter; Naomi Levitt; Viacheslav Mareev; Felipe Martinez; Chantal Masson; Theodore Mazzone; Eduardo Meaney; Richard Nesto; Changyu Pan; Rudolf Prager; Sotirios Raptis; Guy Rutten; Herbert Sandstroem; Frank Schaper; Andre Scheen; Ole Schmitz; Isaac Sinay; Vladimir Soska; Steen Stender; Gyula Tamas; Gianni Tognoni; Jaakko Tuomilehto; Alberto Villamil; Juraj Vozar; Robert Califf

doi:10.1056/NEJMoa1001122

Effect of nateglinide on the incidence of diabetes and cardiovascular events

R Holman, Steven Haffner, John McMurray, M Bethel, Bjoern Holzhauer, Tsushung Hua, Yuri Belenkov, Mitradev Boolell, John Buse, Brendan Buckley, Antonio Chacra, Fu-Tien Chiang, Bernard Charbonnel, Chun-Chung Chow, Melanie Davies, Prakash Deedwania, Peter Diem, Daniel Einhorn, Vivian Fonseca, Gregory FulcherZbigniew Gaciong, Sonia Gaztambide, Thomas Giles, Edward Horton, Hasan Ilkova, Trond Jenssen, Steven Kahn, Henry Krum, Markku Laakso, Lawrence Leiter, Naomi Levitt, Viacheslav Mareev, Felipe Martinez, Chantal Masson, Theodore Mazzone, Eduardo Meaney, Richard Nesto, Changyu Pan, Rudolf Prager, Sotirios Raptis, Guy Rutten, Herbert Sandstroem, Frank Schaper, Andre Scheen, Ole Schmitz, Isaac Sinay, Vladimir Soska, Steen Stender, Gyula Tamas, Gianni Tognoni, Jaakko Tuomilehto, Alberto Villamil, Juraj Vozar, Robert Califf

Epidemiology and Preventive Medicine Alfred Hospital

Research output: Contribution to journal › Article › Research › peer-review

422 Citations (Scopus)

Abstract

The ability of short-acting insulin secretagogues to reduce the risk of diabetes or cardiovascular events in people with impaired glucose tolerance is unknown. In a double-blind, randomized clinical trial, we assigned 9306 participants with impaired glucose tolerance and either cardiovascular disease or cardiovascular risk factors to receive nateglinide (up to 60 mg three times daily) or placebo, in a 2-by-2 factorial design with valsartan or placebo, in addition to participation in a lifestyle modification program.

Original language	English
Pages (from-to)	1463 - 1476
Number of pages	14
Journal	The New England Journal of Medicine
Volume	362
Issue number	16
DOIs	https://doi.org/10.1056/NEJMoa1001122
Publication status	Published - 2010

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1056/NEJMoa1001122

Cite this

Holman, R., Haffner, S., McMurray, J., Bethel, M., Holzhauer, B., Hua, T., Belenkov, Y., Boolell, M., Buse, J., Buckley, B., Chacra, A., Chiang, F-T., Charbonnel, B., Chow, C-C., Davies, M., Deedwania, P., Diem, P., Einhorn, D., Fonseca, V., ... Califf, R. (2010). Effect of nateglinide on the incidence of diabetes and cardiovascular events. The New England Journal of Medicine, 362(16), 1463 - 1476. https://doi.org/10.1056/NEJMoa1001122

@article{8eef3e3468c6445282c314c7f790cda7,

title = "Effect of nateglinide on the incidence of diabetes and cardiovascular events",

abstract = "The ability of short-acting insulin secretagogues to reduce the risk of diabetes or cardiovascular events in people with impaired glucose tolerance is unknown. In a double-blind, randomized clinical trial, we assigned 9306 participants with impaired glucose tolerance and either cardiovascular disease or cardiovascular risk factors to receive nateglinide (up to 60 mg three times daily) or placebo, in a 2-by-2 factorial design with valsartan or placebo, in addition to participation in a lifestyle modification program.",

author = "R Holman and Steven Haffner and John McMurray and M Bethel and Bjoern Holzhauer and Tsushung Hua and Yuri Belenkov and Mitradev Boolell and John Buse and Brendan Buckley and Antonio Chacra and Fu-Tien Chiang and Bernard Charbonnel and Chun-Chung Chow and Melanie Davies and Prakash Deedwania and Peter Diem and Daniel Einhorn and Vivian Fonseca and Gregory Fulcher and Zbigniew Gaciong and Sonia Gaztambide and Thomas Giles and Edward Horton and Hasan Ilkova and Trond Jenssen and Steven Kahn and Henry Krum and Markku Laakso and Lawrence Leiter and Naomi Levitt and Viacheslav Mareev and Felipe Martinez and Chantal Masson and Theodore Mazzone and Eduardo Meaney and Richard Nesto and Changyu Pan and Rudolf Prager and Sotirios Raptis and Guy Rutten and Herbert Sandstroem and Frank Schaper and Andre Scheen and Ole Schmitz and Isaac Sinay and Vladimir Soska and Steen Stender and Gyula Tamas and Gianni Tognoni and Jaakko Tuomilehto and Alberto Villamil and Juraj Vozar and Robert Califf",

year = "2010",

doi = "10.1056/NEJMoa1001122",

language = "English",

volume = "362",

pages = "1463 -- 1476",

journal = "The New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachusetts Medical Society",

number = "16",

}

Holman, R, Haffner, S, McMurray, J, Bethel, M, Holzhauer, B, Hua, T, Belenkov, Y, Boolell, M, Buse, J, Buckley, B, Chacra, A, Chiang, F-T, Charbonnel, B, Chow, C-C, Davies, M, Deedwania, P, Diem, P, Einhorn, D, Fonseca, V, Fulcher, G, Gaciong, Z, Gaztambide, S, Giles, T, Horton, E, Ilkova, H, Jenssen, T, Kahn, S, Krum, H, Laakso, M, Leiter, L, Levitt, N, Mareev, V, Martinez, F, Masson, C, Mazzone, T, Meaney, E, Nesto, R, Pan, C, Prager, R, Raptis, S, Rutten, G, Sandstroem, H, Schaper, F, Scheen, A, Schmitz, O, Sinay, I, Soska, V, Stender, S, Tamas, G, Tognoni, G, Tuomilehto, J, Villamil, A, Vozar, J & Califf, R 2010, 'Effect of nateglinide on the incidence of diabetes and cardiovascular events', The New England Journal of Medicine, vol. 362, no. 16, pp. 1463 - 1476. https://doi.org/10.1056/NEJMoa1001122

TY - JOUR

T1 - Effect of nateglinide on the incidence of diabetes and cardiovascular events

AU - Holman, R

AU - Haffner, Steven

AU - McMurray, John

AU - Bethel, M

AU - Holzhauer, Bjoern

AU - Hua, Tsushung

AU - Belenkov, Yuri

AU - Boolell, Mitradev

AU - Buse, John

AU - Buckley, Brendan

AU - Chacra, Antonio

AU - Chiang, Fu-Tien

AU - Charbonnel, Bernard

AU - Chow, Chun-Chung

AU - Davies, Melanie

AU - Deedwania, Prakash

AU - Diem, Peter

AU - Einhorn, Daniel

AU - Fonseca, Vivian

AU - Fulcher, Gregory

AU - Gaciong, Zbigniew

AU - Gaztambide, Sonia

AU - Giles, Thomas

AU - Horton, Edward

AU - Ilkova, Hasan

AU - Jenssen, Trond

AU - Kahn, Steven

AU - Krum, Henry

AU - Laakso, Markku

AU - Leiter, Lawrence

AU - Levitt, Naomi

AU - Mareev, Viacheslav

AU - Martinez, Felipe

AU - Masson, Chantal

AU - Mazzone, Theodore

AU - Meaney, Eduardo

AU - Nesto, Richard

AU - Pan, Changyu

AU - Prager, Rudolf

AU - Raptis, Sotirios

AU - Rutten, Guy

AU - Sandstroem, Herbert

AU - Schaper, Frank

AU - Scheen, Andre

AU - Schmitz, Ole

AU - Sinay, Isaac

AU - Soska, Vladimir

AU - Stender, Steen

AU - Tamas, Gyula

AU - Tognoni, Gianni

AU - Tuomilehto, Jaakko

AU - Villamil, Alberto

AU - Vozar, Juraj

AU - Califf, Robert

PY - 2010

Y1 - 2010

N2 - The ability of short-acting insulin secretagogues to reduce the risk of diabetes or cardiovascular events in people with impaired glucose tolerance is unknown. In a double-blind, randomized clinical trial, we assigned 9306 participants with impaired glucose tolerance and either cardiovascular disease or cardiovascular risk factors to receive nateglinide (up to 60 mg three times daily) or placebo, in a 2-by-2 factorial design with valsartan or placebo, in addition to participation in a lifestyle modification program.

AB - The ability of short-acting insulin secretagogues to reduce the risk of diabetes or cardiovascular events in people with impaired glucose tolerance is unknown. In a double-blind, randomized clinical trial, we assigned 9306 participants with impaired glucose tolerance and either cardiovascular disease or cardiovascular risk factors to receive nateglinide (up to 60 mg three times daily) or placebo, in a 2-by-2 factorial design with valsartan or placebo, in addition to participation in a lifestyle modification program.

UR - http://www.nejm.org/doi/pdf/10.1056/NEJMoa1001122

U2 - 10.1056/NEJMoa1001122

DO - 10.1056/NEJMoa1001122

M3 - Article

VL - 362

SP - 1463

EP - 1476

JO - The New England Journal of Medicine

JF - The New England Journal of Medicine

SN - 0028-4793

IS - 16

ER -

Effect of nateglinide on the incidence of diabetes and cardiovascular events

Abstract

UN SDGs

Access to Document

Other files and links

Cite this